You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 909.00p
Change Today:
-47.00p
Market Cap:
783.33m
Sector:
Pharmaceuticals & Biotechnology

Oxford Biomedica joins Covid-19 vaccine consortium

By Josh White

Date: Wednesday 08 Apr 2020

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.
The London-listed firm said the vaccine candidate was "one of the leading" vaccine candidates currently in development globally, and was expected to be the UK's first Covid-19 vaccine in clinical trials later in April.

It said the consortium was led by the Jenner Institute at the University of Oxford, and also included the Vaccines Manufacturing and Innovation Centre (VMIC), Pall Life Sciences, Cobra Biologics and Halix BV.

The Jenner Institute and the Oxford Vaccine Group had already recruited individuals aged between 18 and 55 from the Thames Valley area, to study the vaccine's safety and efficacy.

Oxford Biomedica said it would provide access to its large scale GMP manufacturing facilities for viral vectors, including its new Oxbox facility, to the consortium as required, which - along with other consortium manufacturing partners in the UK and internationally - would allow for scaled manufacturing capacity should the safety and efficacy of the vaccine candidate be confirmed in clinical trials.

The Oxford vaccine candidate relied on adenoviral vector technology, 'ChAdOx1', developed at the Jenner Institute in Oxford.

It was seen as "one of the most promising" vaccine technologies for Covid-19, Ocford Biomedica claimed, as ChAdOx1 had been shown to generate a strong immune response from one dose, and had demonstrated a good safety profile in pre-clinical and clinical trials conducted to date.

No financial terms were disclosed in the announcement.

"As an established clinical and commercial manufacturer of viral vectors, we are very pleased to be in a strong position in terms of capacity and capabilities to support the important and urgent efforts of the consortium led by the Jenner Institute, University of Oxford, to develop and scale up manufacturing of this promising vaccine candidate for Covid-19," said chief executive officer John Dawson.

"While our current activities on this vaccine candidate are just initiating, should the consortium confirm there is promise for this candidate in the clinical trial initiating this month, we will play our role within the consortium to scale up manufacturing as fast as possible.

"This will help to provide significant access to the vaccine candidate for further clinical trials and potentially, if approved for use, for many people in the UK and beyond."

At 1611 BST, shares in Oxford Biomedica were up 22.68% at 687p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 909.00p
Change Today -47.00p
52 Week High 1,634.00p
52 Week Low 905.00p
Volume 166,710
Shares Issued 86.18m
Market Cap 783.33m
Beta 0.03

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Price Chg 6m
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 5
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 21-Jan-2022

Time Volume / Share Price
16:37 15,000 @ 911.95p
16:35 30,499 @ 909.00p
16:29 91 @ 916.00p
16:29 8 @ 916.00p
16:29 8 @ 913.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter